Arika Sandbach, PharmD, BCOP

Providence Cancer Institute

Arika Sandbach, PharmD, BCOP, is an oncology pharmacist at Providence Cancer Institute. Her practice focuses on providing care to patients with solid tumors and hematologic malignancies. This includes the management of toxicities associated with targeted therapies in breast cancer, including the metabolic effects of AKT pathway inhibitors and building monitoring plans that are actually feasible for patients to follow.

Published Articles (1)

Managing Capivasertib-Associated Hyperglycemia: A Structured Monitoring Schedule That Patients Can Follow

October 17, 2026

Capivasertib, an oral AKT inhibitor for HR-positive, HER2-negative advanced breast cancer with PIK3CA, AKT1, or PTEN alterations, carries a labeled hyperglycemia risk requiring structured, front-loaded monitoring.